<?xml version="1.0" encoding="UTF-8"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:content="http://purl.org/rss/1.0/modules/content/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://www.gourt.com/Health/Pharmacy/Drugs-and-Medications/F/Fulvestrant.html">
<title>Fulvestrant RSS : Gourt</title>
<link>http://www.gourt.com/Health/Pharmacy/Drugs-and-Medications/F/Fulvestrant.html</link>
<description></description>
<dc:language>en-us</dc:language>
<dc:rights>Copyright 2007, Gourt.com</dc:rights>
<dc:date>2012-02-09T09:40+34:00
</dc:date>
<dc:publisher>rtruog@gourt.com</dc:publisher>
<dc:creator>rtruog@gourt.com</dc:creator>
<dc:subject>Fulvestrant RSS : Gourt</dc:subject>
<syn:updatePeriod>hourly</syn:updatePeriod>
<syn:updateFrequency>1</syn:updateFrequency>
<syn:updateBase>1901-01-01T00:00+00:00</syn:updateBase>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://twitter.com/cancernewsdaily/statuses/167302444064317440" />
  <rdf:li rdf:resource="http://twitter.com/clinicaltrialsn/statuses/167302363990851584" />
  <rdf:li rdf:resource="http://twitter.com/AOSelsevier/statuses/167149125471711232" />
  <rdf:li rdf:resource="http://twitter.com/schoolofsurgery/statuses/166465586359054336" />
 </rdf:Seq>
</items>
</channel>

<item rdf:about="http://twitter.com/cancernewsdaily/statuses/167302444064317440">
<title>Trial Evaluating TKI258 Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer http://t.co/YXiH7z8q</title>
<link>http://twitter.com/cancernewsdaily/statuses/167302444064317440</link>
<description><![CDATA[Trial Evaluating TKI258 Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer http://t.co/YXiH7z8q]]></description>
</item>

<item rdf:about="http://twitter.com/clinicaltrialsn/statuses/167302363990851584">
<title>Trial Evaluating TKI258 Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer http://t.co/KwwfK6oM</title>
<link>http://twitter.com/clinicaltrialsn/statuses/167302363990851584</link>
<description><![CDATA[Trial Evaluating TKI258 Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer http://t.co/KwwfK6oM]]></description>
</item>

<item rdf:about="http://twitter.com/AOSelsevier/statuses/167149125471711232">
<title>Breast cancer update: Watch Dr. Gradishar and Dr. Rugo discuss the implications of fulvestrant and anastrazole as... http://t.co/wtDNrRlH</title>
<link>http://twitter.com/AOSelsevier/statuses/167149125471711232</link>
<description><![CDATA[Breast cancer update: Watch Dr. Gradishar and Dr. Rugo discuss the implications of fulvestrant and anastrazole as... http://t.co/wtDNrRlH]]></description>
</item>

<item rdf:about="http://twitter.com/schoolofsurgery/statuses/166465586359054336">
<title>Fulvestrant is not recommended as alternative to aromatase inhibitors http://t.co/wzOWWAAt</title>
<link>http://twitter.com/schoolofsurgery/statuses/166465586359054336</link>
<description><![CDATA[Fulvestrant is not recommended as alternative to aromatase inhibitors http://t.co/wzOWWAAt]]></description>
</item>

</rdf:RDF>
